Introduction {#S1}
============

BRCA1 and 2 proteins play integral functions in DNA homologous recombination repair (HRR). In normal cells, the HRR pathway is activated in response to DNA double-stranded breaks ([@B1]). In *BRCA 1/2*-deficient cells, HRR is faulty secondary to loss of *BRCA* function, and therefore, other more error-prone DNA repair pathways are activated. These less perfect mechanisms are felt to be accountable, in part, for carcinogenesis. Similarly, tumors with defective HRR mechanisms are more susceptible to the direct DNA damaging effects of chemotherapy.

Homologous recombination repair dysfunction can be exploited as a therapeutic strategy by the use of poly (ADP-ribose) polymerase (PARP) inhibitors, which inhibit PARP proteins, most commonly PARP1 and 2. As part of the base excision repair (BER) pathway, PARP1 attaches long polymers of ADP-ribose on itself, so that, XRCC1 and other repair proteins have the ability to rapidly locate single-stranded DNA breaks ([@B2]--[@B4]). Newer evidence reveals that the exact role of PARP1 in the BER pathway is perhaps more indirect and not yet clearly defined ([@B5]). Recent studies have also shown that PARP1 is more versatile, and has been implicated in other DNA repair pathways, such as the non-homologous end-joining (NHEJ) repair pathway ([@B6], [@B7]).

Several mechanisms by which PARP inhibition in HRR-deficient cells lead to cell death have been investigated. Most notably, the concept of synthetic lethality explains combinatory lethal effects of BER and HR repair dysfunction, whereas alone, HR or BER pathway disruptions are not lethal to the tumor cell ([@B8]). Additionally, other potential mechanisms have been explored including trapping of inhibited PARP1 at sites of DNA damage preventing other repair proteins access, failure to initiate HRR by PARP-dependent BRCA1 recruitment, and activation of the error-prone NHEJ repair pathway leading to genomic instability and subsequent cell death ([@B9]). Knowledge of PARP activity has led to effective treatment strategies for *BRCA 1/2*-germline mutation related tumors.

*BRCA 1/2*-Mutated Ovarian and Breast Cancer {#S2}
============================================

*BRCA 1/2*-mutation related ovarian and breast cancers account for 5--10% of all female ovarian and breast cancers ([@B10], [@B11]). Ovarian cancers in the setting of *BRCA 1/2*-germline mutations can present with more aggressive, high-grade histologies, but are frequently responsive to chemotherapy, particularly platinum-based regimens, leading to an improved 5 years survival ([@B12]). The chemotherapy-sensitive mechanism is felt to be related to the intimate relationship between BRCA 1/2 proteins and defective HRR, as discussed above. Recent studies have demonstrated that women with *BRCA*-related ovarian cancers fare much better than sporadic ovarian cancers ([@B13]--[@B16]). A study, published by the National Israeli Study of Ovarian Cancer, showed women with *BRCA* mutations had a median survival of 55.7 months compared to 37.9 months in sporadic ovarian cancers (*p* = 0.002) ([@B15]). This may be in part explained by the standard use of carboplatin-based therapies for ovarian malignancies as the DNA damage induced by the platinum should be more efficacious in the DNA repair-deficient *BRCA*-related tumors.

Contrary to the more convincing outcomes in *BRCA 1/2*-related ovarian cancers, the outcomes of *BRCA* mutation-related breast cancers are less clear. Women with *BRCA1* mutations typically develop breast cancer at an earlier age than *BRCA2*-related and sporadic breast cancers. *BRCA1*-related breast cancers tend to also be higher grade, hormone receptor-negative, and HER-2-negative, or "triple negative" ([@B17]), and also frequently express a basal phenotype ([@B18]--[@B26]). Patients with *BRCA*-mutated breast cancers generally respond to therapy as well as sporadic cancers; however, the risk of second ipsilateral or contralateral primaries may be as high as 3--5% per year, compared to 0.5--1% per year risk, seen in sporadic breast cancers ([@B17]). In contrast to ovarian cancer, platinum chemotherapy is not standardly administered to patients with breast cancer. The use of platinum agents has been evaluated in a small series which have demonstrated high efficacy in breast cancer in particular in the setting of a *BRCA* mutation. Silver et al. evaluated the use of neoadjuvant platinum-containing chemotherapy in patients with triple negative breast cancer (TNBC) (*N* = 28), and found those more likely to be platinum-sensitive were those with low *BRCA1* gene expression ([@B27]). Likewise, in *BRCA*-mutated breast cancer patients who received cisplatin in the neoadjuvant setting showed a high rate of pathologic complete response (pCR) in a small series. Ten of 12 patients achieved pCR (83%). When non-platinum-containing regimens were used, the pCR rate was 14% ([@B28]). These studies highlight the rationale to further explore the use of platinum-containing regimens, specifically for patients with TNBC and *BRCA* mutations.

BRCAness: Sporadic Triple Negative Breast Cancers {#S3}
=================================================

Triple negative breast cancers account for \~20% of all breast cancers and are associated with an aggressive clinical picture ([@B20], [@B25], [@B29]). Due to lack of hormone receptor or HER-2 expression, and no other known target for tailored therapy, the only current treatment option is chemotherapy. Over 80% of hereditary *BRCA1*-mutated cancers are TNBCs. Several studies have investigated a potential role for *BRCA1* inactivation in sporadic TNBC given the similar clinical outcomes and histological characteristics among these cancers and hereditary *BRCA1*-mutated breast cancers. Breast cancers developing in patients with *BRCA1* mutations, in addition to frequently being triple negative, also often express basal markers ([@B18]--[@B22], [@B25], [@B26]). Gene microarray expression profiling has shown considerable similarities between *BRCA1*-mutated tumors and basal tumors ([@B25]). This shared phenotype has been termed "BRCAness" ([@B26]). What is unknown is whether the basal phenotype is a result of the *BRCA* loss or if the *BRCA* loss results in the basal phenotype ([@B6]).

Recently, Lehmann and colleagues delved further into the characterization of TNBC. They performed an analysis of gene expression profiles of 587 TNBC cases and identified six separate subtypes of TNBC. These six subtypes were: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR) subtype. Additional analysis of TNBC cell lines, representative of each of these identified subsets, revealed differential responses to various therapeutic agents. Both the BL1 and BL2 groups showed increased gene expression involved in DNA damage response, and showed higher response to cisplatin ([@B30]). In a follow-up study, Masuda et al. presented neoadjuvant chemotherapy response data in each of the aforementioned TNBC subtypes ([@B31]). In 130 TNBC patients, who received standard anthracycline- and taxane-based chemotherapy, the BL1 subtype achieved a pCR most frequently (52%). In contrast, the pCR in the BL2 subtype was 0%. The molecular differences in BL1 and BL2 may explain these differential responses. Specifically, the BL1 subtype involves the cell cycle, DNA replication reactome, and the *BRCA* pathway, among others, whereas the BL2 subtype involves growth factor, glycolysis, and gluconeogenesis pathways. This work demonstrates that even within "basal-like breast cancer (BLBC)," there may be a great deal of heterogeneity.

Telli and colleagues recently presented a study evaluating gemcitabine, carboplatin, and iniparib, a compound initially believed to have PARP inhibitory effects, in the neoadjuvant treatment of triple negative and *BRCA*-mutated breast cancer ([@B32]). This study demonstrated a pCR of 36% overall, with a pCR in *BRCA 1/2*-mutation carriers of 47%. Furthermore, patients who were both triple negative and had a *BRCA 1/2*-mutation, had a pCR of 56%. Although only 10 patients were classified as BL1 or BL2, there were an equal number of responders and non-responders to the neoadjuvant platinum regimen. It is also notable that only one patient classified as basal-like had a known *BRCA* mutation, whereas, there were *BRCA*-mutated tumors that were classified as IM, M, MSL, and unspecified ([@B32]). Although basal-like TNBC has become nearly synonymous with BRCAness, this study found that the basal-like subtype of TNBC was neither particularly responsive to the treatment combination, nor had a higher number of *BRCA*-germline mutations. In this study, the homologous recombination deficiency (HRD) score appeared to be more predictive of platinum response, as compared to TNBC intrinsic subtyping ([@B30]). The HRD assay has been developed to evaluate for loss of heterozygosity (LOH), which has been shown to be predictive of response to platinum in *BRCA*-related and sporadic cancers ([@B33]). While, this data is hypothesis-generating and thought-provoking, larger, prospective studies will be needed before any formal conclusions can be drawn.

In sporadic basal tumors, there are data that show reduced BRCA1 mRNA expression. It is felt that epigenetic modification of the *BRCA* gene, such as promoter hypermethylation, is responsible for this ([@B34]--[@B36]). Interestingly, no tumors showed both *BRCA1* mutation and *BRCA1* promoter methylation suggesting that these events are mutually exclusive in The Cancer Genome Atlas (TCGA) research network data ([@B37]). The association between *BRCA1*-mutated and BLBCs provides an important rationale to include this frequently encountered patient population in studies geared toward manipulation of the characteristic faulty DNA repair mechanisms in *BRCA1*-mutated tumors. As we move into an era where genomic analyses of tumors is becoming the norm, it will be important to link the genome, methylome, and proteome to clinical characteristics and outcomes.

BRCAness: Sporadic High-Grade Serous Ovarian Cancers {#S4}
====================================================

Similarly, there are many commonalities among *BRCA 1/2*-mutated cancers and sporadic epithelial ovarian cancers (EOCs). Although only 5--10% of ovarian cancers are directly attributable to a germline mutation in *BRCA1* or *2*, there is a growing body of evidence to suggest that additional mechanisms of *BRCA* dysfunction are involved in the pathogenesis of ovarian cancer ([@B26], [@B38], [@B39]). One study demonstrated alterations of *BRCA1* and/or *2* in up to 82% of examined ovarian cancers (*n* = 92) ([@B40]). Methylation of the *BRCA1* promoter has been demonstrated in up to 14% of sporadic breast and up to 30% of sporadic ovarian cancers ([@B26], [@B35], [@B41]--[@B46]). LOH has been described in ovarian tumors and may have multiple possible mechanisms leading to malignancy including co-existing LOH of *BRCA1* and *p53*, and hypermethylation acting in a synergistic fashion ([@B33], [@B47]--[@B51]). In contrast, *BRCA2* methylation has not been found to be a significant contributor ([@B39], [@B52]). Identifying and manipulating these *BRCA*-like deficiencies in DNA repair in sporadic ovarian cancers is of great importance and provides rationale for including these patients in clinical trials designed for *BRCA*-related malignancies.

Another important mechanism of BRCAness in ovarian cancers is the presence of somatic mutations in *BRCA1* and *2* ([@B53]). Hennessy and colleagues performed *BRCA1/2* sequencing on 235 unselected ovarian cancers and found that 19% of the sample had detectable mutations in *BRCA1* (*N* = 31) or *BRCA2* (*N* = 13). In the 28 samples, where germline DNA was also available, 42.9% of the *BRCA1* mutations and 28.6% of the *BRCA2* mutations were somatic. Of interest, somatic *BRCA 1/2*-mutations in breast cancer appear to be less frequent. In the TCGA BLBC cohort, about 20% had either germline (*N* = 12) or somatic (*N* = 8) *BRCA 1/2*-mutations. Another study evaluated 77 TNBC samples and only one harbored a somatic *BRCA* mutation ([@B54]). This potentially explains the seemingly higher activity of single agent PARP inhibitors, discussed later, in sporadic ovarian cancer as compared to sporadic TNBC.

Genomic Similarities: Basal-Like Breast Cancer and High-Grade Serous Ovarian Cancers {#S5}
====================================================================================

The Cancer Genome Atlas network recently published findings again demonstrating the four distinct molecular signatures in breast cancer from diverse genetic and epigenetic alterations: luminal A, luminal B, basal-like, and HER-2 enriched subtypes ([@B55]). Strikingly, BLBCs were notably different than the other three subtypes based on comprehensive analyses using multiple platforms. As expected, these cancers also often (80%) lacked expression of ER, PR, and HER-2 identifying as TNBCs. Specifically, most BLBCs showed a high frequency of *TP53* deleterious mutations (80%), as well as, loss of *RB1* and *BRCA1*. *PIK3CA* mutations (\~9%) were also a common feature of BLBC. Analyses also highlighted increased *MYC* activation as a BLBC characteristic.

The BLBC mutation spectrum reported in the TCGA was similar to that identified in previously described serous ovarian cancers ([@B56]) and BLBC were more similar to serous ovarian carcinomas than to other subtypes of breast cancer. One gene, in particular, *TP53*, had a \>10% mutation frequency in both basal-like breast and serous ovarian cancers. As well, both tumors when compared to luminal showed increased *BRCA1* inactivation, *RB1* loss, cyclin E1 amplification, high expression of *AKT3*, and *MYC* amplification. These molecular commonalities strongly suggest shared driving events in tumorigenesis, and similarly, show support for shared treatment strategies for TNBCs and high-grade serous ovarian cancers. Of note, *p53* mutations have been described to have high frequency in *BRCA* mutation-related cancers as well ([@B57], [@B58]).

PARP Inhibitors: Preclinical Era {#S6}
================================

Bryant et al. and Farmer et al. demonstrated synthetic lethality in *BRCA2*-deficient cells with the use of two different PARP inhibitors ([@B59], [@B60]). PARP inhibitors have also shown efficacy preclinically in cells lacking other HRR proteins, such as *RAD51*, *ATR*, *ATM*, *CHK1*, and *FANCA* or *FANCC* ([@B61]). These studies have given basis for clinical trials in both *BRCA*-deficient cancer populations, as well as, those with malignancies sharing qualities of BRCAness or HRR-deficiency, such as basal-like or TNBC and serous ovarian cancer.

PARP Inhibitors in Clinical Trials {#S7}
==================================

*BRCA 1/2*-mutation studies {#S7-1}
---------------------------

The first published Phase I study evaluating PARP inhibitors in the clinic used olaparib (AZD2281) enrolling patients with varying malignancies (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) ([@B62]). An expansion cohort of *BRCA*-positive ovarian, breast, and prostate cancer patients was enrolled at the recommended Phase II dose of 400 mg twice daily. Nearly half of the evaluable patients had an objective response (19 patients, 47%). Results from this pivotal study showed olaparib was generally well tolerated. From here, two Phase II proof-of-concept trials (ICEBERG 1 and 2) (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) confirmed activity in both *BRCA*-mutated ovarian and breast cancers, with olaparib at 400 mg twice daily \[ORR 11/33 (33%) and 11/27 (41%), respectively\], with low overall toxicities ([@B63], [@B64]).

Olaparib was also evaluated in patients with sporadic cancers displaying a presumed BRCAness phenotype. Gelmon et al. performed a non-randomized Phase II trial using olaparib in heavily treated high-grade serous or undifferentiated ovarian carcinomas and TNBCs ([@B65]) (Tables [1](#T1){ref-type="table"}--[4](#T4){ref-type="table"}). Stratified by *BRCA* mutation status, both *BRCA*-mutated and *BRCA*-wild type ovarian carcinoma patients showed response to olaparib. In contrast, neither *BRCA*-mutated nor sporadic breast cancer patients demonstrated significant response to olaparib. Potential explanations for these mixed results include that not all TNBCs have a *BRCA*-like phenotype, so there may have been some heterogeneity to this population ([@B30]).

###### 

**Selected PARP inhibitor trials in *BRCA 1/2*-mutated (*BRCA*^mut^) breast cancers**.

  Trial                                               Study population                                                                                                                      PARP inhibitor                                  Comparison therapy   Clinical responses[^a^](#tfn1){ref-type="table-fn"}
  --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- -------------------- -----------------------------------------------------------------------------------------------
  Phase I                                             Advanced *BRCA*ut^mut^ tumors (*N* = 39, of which 8 BC)                                                                               BMN 673                                         None                 *BRCA*ut^mut^ BC
  De Bono et al. ([@B71])                                                                                                                                                                                                                                        ORR: 2/6
  NCT01286987                                                                                                                                                                                                                                                    
  Phase I                                             Advanced solid tumors/hematologic malignancies (*N* = 100, of which 12 BC, including 4 *BRCA*ut^mut^)                                 Niraparib                                       None                 *BRCA*ut^mut^ BC
  Sandhu et al. ([@B68])                                                                                                                                                                                                                                         PR: 2/4
  NCT00749502                                                                                                                                                                                                                                                    
  Phase I                                             Advanced solid tumors                                                                                                                 Olaparib                                        None                 *BRCA*ut^mut^ BC
  Fong et al. ([@B62])                                *N* = 60, of which 9 BC, including 3 with *BRCA*ut^mut^                                                                                                                                                    CR: 1/3
  NCT00516373                                                                                                                                                                                                                                                    SD: 1/3
  Phase II                                            Recur, advanced *BRCA*ut^mut^ OC (*N* = 17)/BC (*N* = 10), or *BRCA*t^wt^ HGS and/or undifferentiated OC (*N* = 47)/TNBC (*N* = 16)   Olaparib                                        None                 *BRCA*ut^mut^ BC
  Gelmon et al. ([@B65])                                                                                                                                                                                                                                         CR + PR: 0/8
  NCT00679783                                                                                                                                                                                                                                                    SD: 5/8
  Phase II                                            *BRCA*ut^mut^ solid tumors (BC, *N* = 62, OC, *N* = 193)                                                                              Olaparib                                        None                 *BRCA*ut^mut^ BC
  Kaufman et al. ([@B89])                                                                                                                                                                                                                                        CR: 0/62
  NCT01078662                                                                                                                                                                                                                                                    PR: 8/62
                                                                                                                                                                                                                                                                 SD: 29/62
                                                                                                                                                                                                                                                                 PFS rate: 29% for 6 months
                                                                                                                                                                                                                                                                 OS rate: 44.7% for 12 months
  Phase II                                            *BRCA*ut^mut^ advanced BC (*N* = 27)                                                                                                  Olaparib                                        None                 ORR: 11/27
  Tutt et al. ([@B64])                                                                                                                                                                                                                                           CR: 1/27
  NCT00494234                                                                                                                                                                                                                                                    PR: 10/27
  ICEBERG 1                                                                                                                                                                                                                                                      PFS: 5.7 months
  Phase I                                             Met or unresect *BRCA*ut^mut^ BC and EOC (*N* = 45, of which 8 BC)                                                                    Olaparib + carboplatin                          None                 *BRCA*ut^mut^ BC
  Lee et al. ([@B72])                                                                                                                                                                                                                                            CR: 1/8
  NCT00647062, NCT01445418                                                                                                                                                                                                                                       PR: 6/8
                                                                                                                                                                                                                                                                 SD: 1/8
  Phase I                                             Advanced solid tumors \[*N* = 87, including BC (26%) and OC (7%), of which 12 *BRCA*ut^mut^\]                                         Olaparib + carboplatin ± paclitaxel             None                 *BRCA*ut^mut^
  van der Noll et al. ([@B90])                                                                                                                                                                                                                                   CR: 17%[^b^](#tfn2){ref-type="table-fn"}
  NCT00516724                                                                                                                                                                                                                                                    PR: 33%[^b^](#tfn2){ref-type="table-fn"}
  Phase I                                             Recur or advanced EOC/TNBC                                                                                                            Olaparib + cediranib (angiogenesis inhibitor)   None                 *BRCA*ut^mut^ BC
  Liu et al. ([@B82])                                 *N* = 28, of which 3 *BRCA*ut^mut^ BC                                                                                                                                                                      ORR: 0/3
  NCT01116648                                                                                                                                                                                                                                                    
  Phase I/II Kristeleit et al. ([@B69]) NCT01482715   Advanced solid tumors and relapsed PSens *BRCA*ut^mut^ OC                                                                             Rucaparib                                       None                 *BRCA*ut^mut^ BC PR: 1/17
                                                      *N* = 29, of which 17 BC and 7 OC, including *BRCA*ut^mut^ tumors                                                                                                                                          SD: 10/29 (of which 4 were BC, also 7/10 were *BRCA*ut^mut^)[^b^](#tfn2){ref-type="table-fn"}
  Phase I                                             Advanced *BRCA*ut^mut^ solid tumors (*N* = 38, of which 12 BC), or *BRCA*t^wt^ BLBC or OC                                             Veliparib                                       None                 *BRCA*ut^mut^ BC
  Huggins-Puhalla et al. ([@B91])                                                                                                                                                                                                                                PR: 1/12
  NCT00892736                                                                                                                                                                                                                                                    SD: 10/38[^b^](#tfn2){ref-type="table-fn"}
  Phase I Ramaswamy et al. ([@B92]) NCT01251874       Met or unresect *BRCA*ut^mut^ BC, or *BRCA*t^wt^ TNBC and other BCs                                                                   Veliparib + carboplatin                         None                 *BRCA*ut^mut^ BC PR: 2/6
                                                      *N* = 38, of which 6 *BRCA*ut^mut^ and 7 FAef[^def^](#tfn4){ref-type="table-fn"}                                                                                                                           SD: 4/6
                                                                                                                                                                                                                                                                 PR: 8/38[^b^](#tfn2){ref-type="table-fn"}
                                                                                                                                                                                                                                                                 SD: 17/38[^b^](#tfn2){ref-type="table-fn"}
  Phase I                                             Met or unresect *BRCA*ut^mut^ BC                                                                                                      Veliparib + carboplatin                         None                 CR: 3/26[^b^](#tfn2){ref-type="table-fn"}
  Somlo et al. ([@B93])                               *N* = 28                                                                                                                                                                                                   PR: 9/26
  NCT01149083                                                                                                                                                                                                                                                    SD: 7/26
                                                                                                                                                                                                                                                                 PFS: 7.8 months
  Phase I Rodler et al. ([@B94]) NCT01104259          Met *BRCA*ut^mut^ BC or recur and/or met *BRCA*t^wt^ TNBC                                                                             Veliparib + cisplatin and vinorelbine           None                 *BRCA*ut^mut^ BC PR: 3/5
                                                      *N* = 18, of which 5 *BRCA1/2*ut^mut^                                                                                                                                                                      
                                                                                                                                                                                                                                                                 PR: 6/11[^b^](#tfn2){ref-type="table-fn"}
                                                                                                                                                                                                                                                                 SD: 5/11[^b^](#tfn2){ref-type="table-fn"}
  Phase I                                             Met BC                                                                                                                                Veliparib + cyclophosphamide and doxorubicin    None                 PR: 2/11 (both *BRCA2*ut^mut^)
  Tan et al. ([@B95])                                 *N* = 11, of which 3 *BRCA2*ut^mut^                                                                                                                                                                        SD: 6/11 (of which 1 *BRCA2*ut^mut^)
  NCT00740805                                                                                                                                                                                                                                                    
  Phase II                                            Met *BRCA*ut^mut^ BC (expansion cohort, *N* = 24)                                                                                     Veliparib + temozolomide                        None                 CR: 1/24
  Isakoff et al. ([@B96])                                                                                                                                                                                                                                        PR: 2/24
  NCT01009788                                                                                                                                                                                                                                                    SD: 7/24

*^a^Data include only patients with measurable disease*.

*^b^Collective data reported*.

*BC, breast cancer; ORR, objective response rate; PR, partial response; CR, complete response; SD, stable disease; recur, recurrent; OC, ovarian cancer; *BRCA*^wt^, *BRCA*-wild type; HGS, high-grade serous; TNBC, triple negative breast cancer; PFS, progression-free survival; OS, overall survival; met, metastatic; unresect, unresectable; EOC, epithelial ovarian cancer; PSens, platinum-sensitive; BLBC, basal-like breast cancer; FA^def^, fanconi anemia pathway deficiency*.

###### 

**Selected PARP inhibitor trials in *BRCA 1/2*-mutated (*BRCA*^mut^) ovarian cancers**.

  Trial                                               Study population                                                                                                                       PARP inhibitor                                  Comparison therapy      Clinical responses[^a^](#tfn3){ref-type="table-fn"}
  --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------- -----------------------------------------------------------------------------------------------
  Phase I                                             Advanced *BRCA*ut^mut^ tumors (*N* = 39, of which 8 BC and 23 OC)                                                                      BMN 673                                         None                    *BRCA*ut^mut^ OC
  De Bono et al. ([@B71])                                                                                                                                                                                                                                            ORR: 11/17
  NCT01286987                                                                                                                                                                                                                                                        
  Phase I                                             Advanced solid tumors/hematologic malignancies (*N* = 100, of which 49 OC, including 22 *BRCA*ut^mut^)                                 Niraparib                                       None                    *BRCA*ut^mut^ OC
  Sandhu et al. ([@B68])                                                                                                                                                                                                                                             PR: 8/20
  NCT00749502                                                                                                                                                                                                                                                        
  Phase I                                             Advanced solid tumors                                                                                                                  Olaparib                                        None                    *BRCA*ut^mut^ OC
  Fong et al. ([@B62])                                *N* = 60, of which 21 OC, including 16 with *BRCA*ut^mut^                                                                                                                                                      PR: 8/15
  NCT00516373                                                                                                                                                                                                                                                        SD: 1/15
  Phase II                                            Recur, advanced *BRCA*ut^mut^ OC (*N* = 17)/BCs (*N* = 10), or *BRCA*t^wt^ HGS and/or undifferentiated OC (*N* = 47)/TNBC (*N* = 16)   Olaparib                                        None                    *BRCA*ut^mut^ OC
  Gelmon et al. ([@B65])                                                                                                                                                                                                                                             CR: 0/17
  NCT00679783                                                                                                                                                                                                                                                        PR: 7/17
                                                                                                                                                                                                                                                                     SD: 6/17
  Phase II                                            Advanced PRef or PRes *BRCA*ut^mut^ OC                                                                                                 Olaparib                                        Liposomal doxorubicin   Olaparib 200 mg twice daily
  Kaye et al. ([@B66])                                                                                                                                                                                                                                               PFS: 6.5 months
  NCT00628251                                                                                                                                                                                                                                                        ORR: 25%
                                                                                                                                                                                                                                                                     Olaparib 400 mg twice daily
                                                                                                                                                                                                                                                                     PFS: 8.8 months
                                                                                                                                                                                                                                                                     ORR: 31%
                                                                                                                                                                                                                                                                     Liposomal doxorubicin:
                                                                                                                                                                                                                                                                     PFS: 7.1 months
                                                                                                                                                                                                                                                                     ORR: 18%
  Phase II                                            *BRCA*ut^mut^ solid tumors (BC, *N* = 62, OC, *N* = 193)                                                                               Olaparib                                        None                    *BRCA*ut^mut^ OC
  Kaufman et al. ([@B89])                                                                                                                                                                                                                                            CR: 6/193
  NCT01078662                                                                                                                                                                                                                                                        PR: 54/193
                                                                                                                                                                                                                                                                     SD: 78/193
                                                                                                                                                                                                                                                                     PFS rate: 54.6% for 6 months
                                                                                                                                                                                                                                                                     OS rate: 64.4% for 12 months
  Phase II                                            Advanced *BRCA*ut^mut^ OC                                                                                                              Olaparib                                        None                    ORR: 11/33
  Audeh et al. ([@B63])                                                                                                                                                                                                                                              CR: 2/33
  NCT00494442                                                                                                                                                                                                                                                        PR: 9/33
                                                                                                                                                                                                                                                                     PFS: 5.8 months
  Phase I                                             Met or unresect *BRCA*ut^mut^ BC and EOC (*N* = 45, of which 37 OC)                                                                    Olaparib + carboplatin                          None                    *BRCA*ut^mut^ OC
  Lee et al. ([@B72])                                                                                                                                                                                                                                                CR: 0/34
  NCT00647062, NCT01445418                                                                                                                                                                                                                                           PR: 15/34
                                                                                                                                                                                                                                                                     SD: 14/34
  Phase I                                             Advanced solid tumors *N* = 87, including BC (26%) and OC (7%), of which 12 *BRCA*ut^mut^                                              Olaparib + carboplatin ± paclitaxel             None                    *BRCA*ut^mut^
  van der Noll et al. ([@B90])                                                                                                                                                                                                                                       CR: 17%[^b^](#tfn4){ref-type="table-fn"}
  NCT00516724                                                                                                                                                                                                                                                        PR: 33%[^b^](#tfn4){ref-type="table-fn"}
  Phase I                                             Recur or advanced EOC/TNBC                                                                                                             Olaparib + cediranib (angiogenesis inhibitor)   None                    *BRCA*ut^mut^ OC
  Liu et al. ([@B82])                                 *N* = 28, of which 12 *BRCA*ut^mut^ OC                                                                                                                                                                         CR: 1/11
  NCT01116648                                                                                                                                                                                                                                                        PR: 4/11
  Phase I/II Kristeleit et al. ([@B69]) NCT01482715   Advanced solid tumors and relapsed PSens *BRCA*ut^mut^ OC                                                                              Rucaparib                                       None                    *BRCA*ut^mut^ OC PR: 1/7
                                                      *N* = 29, of which 17 BC and 7 OC, including *BRCA*ut^mut^ tumors                                                                                                                                              SD: 10/29 (of which 5 were OC, also 7 were *BRCA*ut^mut^)[^b^](#tfn4){ref-type="table-fn"}
                                                                                                                                                                                                                                                                     CR + PR + SD: 6/7 in OC
  Phase I                                             Advanced *BRCA*ut^mut^ solid tumors (*N* = 38, of which 20 OC), or *BRCA*t^wt^ BLBC or OC                                              Veliparib                                       None                    *BRCA*ut^mut^ OC
  Huggins-Puhalla et al. ([@B91])                                                                                                                                                                                                                                    PR: 1/20
  NCT00892736                                                                                                                                                                                                                                                        SD: 10/38[^b^](#tfn4){ref-type="table-fn"}
  Phase II Kummar et al. ([@B97]) NCT01306032         Refractory progressive *BRCA*ut^mut^ OC or HGS OC                                                                                      Veliparib (V) + cyclophosphamide (C)            Cyclophosphamide (C)    V + C: PR: 3/36[^b^](#tfn4){ref-type="table-fn"} C: PR: 5/38[^b^](#tfn4){ref-type="table-fn"}
                                                                                                                                                                                             *N* = 36                                        *N* = 38                
  Phase I                                             Met or unresect solid tumors                                                                                                           Veliparib + carboplatin and gemcitabine         None                    CR: 2/59[^b^](#tfn4){ref-type="table-fn"}
  Bell-McGuinn et al. ([@B98])                        *N* = 59, of which 39 OC, 24 of 39 OC *BRCA*ut^mut^                                                                                                                                                            PR: 11/59[^b^](#tfn4){ref-type="table-fn"}
  NCT01063816                                                                                                                                                                                                                                                        Of 13 responses, 8 *BRCA*ut^mut^ OC, 3 other OC

*^a^Data include only patients with measurable disease*.

*^b^Collective data reported*.

*BC, breast cancer; OC, ovarian cancer; ORR, objective response rate; PR, partial response; SD, stable disease; recur, recurrent; *BRCA*^wt^, *BRCA*-wild type; HGS, high-grade serous; TNBC, triple negative breast cancer; PRef, platinum-refractory; PRes, platinum-resistant; PFS, progression free survival; OS, overall survival; CR, complete response; met, metastatic; unresect, unresectable; EOC, epithelial ovarian cancer; PSens, platinum-sensitive; BLBC, basal-like breast cancer*.

###### 

**Selected PARP inhibitor trials in sporadic breast cancers**.

  Trial                                           Study population                                                                                                                        PARP inhibitor                                  Comparison therapy   Clinical responses[^a^](#tfn7){ref-type="table-fn"}
  ----------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- -------------------- -------------------------------------------------------------------------------------
  Phase II                                        Recur, advanced *BRCA*ut^mut^ OC (*N* = 17)/BCs (*N* = 10), or *BRCA*t^wt^ HGS, and/or undifferentiated OC (*N* = 47)/TNBC (*N* = 16)   Olaparib                                        None                 *BRCA*t^wt^ TNBC
  Gelmon et al. ([@B65])                                                                                                                                                                                                                                       CR + PR: 0/15
  NCT00679783                                                                                                                                                                                                                                                  SD: 2/15
  Phase I                                         Refractory or recur BC (*N* = 4) and OC                                                                                                 Olaparib + carboplatin                          None                 BC
  Lee et al. ([@B99])                                                                                                                                                                                                                                          PR: 3/4
  NCT01237067                                                                                                                                                                                                                                                  SD: 1/4
  Phase I                                         Advanced solid tumors *N* = 87, including BC (26%) and OC (7%), of which 12 *BRCA*ut^mut^                                               Olaparib + carboplatin ± paclitaxel             None                 ORR: 14/87 (16%)[^b^](#tfn8){ref-type="table-fn"}
  van der Noll et al. ([@B90])                                                                                                                                                                                                                                 CR: 5%
  NCT00516724                                                                                                                                                                                                                                                  PR: 11%
                                                                                                                                                                                                                                                               SD: 28%
  Phase I                                         Recur or advanced EOC/TNBC                                                                                                              Olaparib + cediranib (angiogenesis inhibitor)   None                 BC
  Liu et al. ([@B82])                             *N* = 28, of which 8 BC                                                                                                                                                                                      ORR: 0/7
  NCT01116648                                                                                                                                                                                                                                                  SD: 2/7
  Phase I                                         Advanced solid tumors                                                                                                                   Olaparib + cisplatin                            None                 CR: 1/54[^b^](#tfn8){ref-type="table-fn"}
  Balmana et al. ([@B100])                        *N* = 54, of which 42 BC                                                                                                                                                                                     PR: 17/54[^b^](#tfn8){ref-type="table-fn"}
  NCT00782574                                                                                                                                                                                                                                                  SD: 23/54[^b^](#tfn8){ref-type="table-fn"}
  Phase I                                         Met TNBC                                                                                                                                Olaparib + paclitaxel                           None                 PR: 7/19
  Dent et al. ([@B76])                            *N* = 19                                                                                                                                                                                                     SD: 1/19
  NCT00707707                                                                                                                                                                                                                                                  
  Phase I                                         Advanced *BRCA*ut^mut^ solid tumors, or *BRCA*t^wt^ tumors (*N* = 25, of which 21 BLBC)                                                 Veliparib                                       None                 *BRCA*t^wt^ BLBC
  Huggins-Puhalla et al. ([@B91])                                                                                                                                                                                                                              PR: 1/21
  NCT00892736                                                                                                                                                                                                                                                  *BRCA*t^wt^
                                                                                                                                                                                                                                                               SD: 7/25[^b^](#tfn8){ref-type="table-fn"}
  Phase I                                         Refractory solid tumors/lymphoma                                                                                                        Veliparib                                       Cyclophosphamide     PR: 7/35[^b^](#tfn8){ref-type="table-fn"}
  Kummar et al. ([@B101])                         *N* = 35, including BC and OC                                                                                                                                                                                SD: 6/35[^b^](#tfn8){ref-type="table-fn"}
  NCT00810966                                                                                                                                                                                                                                                  
  Phase I Ramaswamy et al. ([@B92]) NCT01251874   Met or unresect *BRCA*ut^mut^ BC, or *BRCA*t^wt^ TNBC and other BCs                                                                     Veliparib + carboplatin                         None                 PR: 8/38 SD: 17/38
                                                  *N* = 38, of which 6 *BRCA*ut^mut^ and 7 FAef^def^                                                                                                                                                           
                                                                                                                                                                                                                                                               FAef^def^
                                                                                                                                                                                                                                                               PR: 2/7
                                                                                                                                                                                                                                                               SD: 5/7
  Phase I                                         Met or unresect solid tumors                                                                                                            Veliparib + carboplatin and gemcitabine         None                 CR: 2/59[^b^](#tfn8){ref-type="table-fn"}
  Bell-McGuinn et al. ([@B98])                    *N* = 59, of which 10 BC                                                                                                                                                                                     PR: 11/59[^b^](#tfn8){ref-type="table-fn"}
  NCT01063816                                                                                                                                                                                                                                                  Of 13 responses, 8 *BRCA*ut^mut^ OC, 3 other OC, 2 others
  Phase I                                         Advanced solid tumors including BC                                                                                                      Veliparib + carboplatin and paclitaxel          None                 BC
  Appleman et al. ([@B102])                       *N* = 68, of which 14 BC                                                                                                                                                                                     CR: 3/14
  NCT00535119                                                                                                                                                                                                                                                  PR: 5/14
  Phase I                                         Met or unresect solid tumors, including BC (Q1 week, *N* = 10 TNBC, Q3 week, *N* = 9 TNBC)                                              Veliparib + carboplatin and paclitaxel          None                 TNBC
  Puhalla et al. ([@B80]) NCT01281150                                                                                                                                                                                                                          (Q1 week), CR: 2/10, PR: 3/10, SD: 3/10
                                                                                                                                                                                                                                                               (Q3 week), CR: 3/9, PR: 4/9, SD: 1/9
  Phase I Rodler et al. ([@B94]) NCT01104259      Met *BRCA*ut^mut^ BC or recur and/or met *BRCA*t^wt^ TNBC                                                                               Veliparib + cisplatin and vinorelbine           None                 PR: 6/11[^b^](#tfn8){ref-type="table-fn"} SD: 5/11[^b^](#tfn8){ref-type="table-fn"}
                                                  *N* = 18, of which 5 *BRCA1/2*ut^mut^                                                                                                                                                                        
  Phase I Tan et al. ([@B95]) NCT00740805         Met BC                                                                                                                                  Veliparib + cyclophosphamide and doxorubicin    None                 PR: 2/11 (both *BRCA2*ut^mut^)
                                                  *N* = 11, of which 3 *BRCA2*ut^mut^                                                                                                                                                                          SD: 6/11 (of which 1 *BRCA2*ut^mut^)

*^a^Data include only patients with measurable disease*.

*^b^Collective data reported*.

*recur, recurrent; *BRCA*^mut^, mutated *BRCA*; OC, ovarian cancer; BC, breast cancer; *BRCA*^wt^, *BRCA*-wild type; HGS, high-grade serous; TNBC, triple negative breast cancer; CR, complete response; PR, partial response; SD, stable disease; ORR, objective response rate; EOC, epithelial ovarian cancer; met, metastatic; BLBC, basal-like breast cancer; FA^def^, fanconi anemia pathway deficiency*.

###### 

**Selected PARP inhibitor trials in sporadic ovarian cancers**.

  Trial                                         Study population                                                                                                                       PARP inhibitor                                  Comparison therapy              Clinical responses[^a^](#tfn5){ref-type="table-fn"}
  --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- -----------------------------------------------------------
  Phase II                                      Recur, advanced *BRCA*ut^mut^ OC (*N* = 17)/BCs (*N* = 10), or *BRCA*t^wt^ HGS and/or undifferentiated OC (*N* = 47)/TNBC (*N* = 16)   Olaparib                                        None                            *BRCA*t^wt^ OC
  Gelmon et al. ([@B65])                                                                                                                                                                                                                                               CR: 0/46
  NCT00679783                                                                                                                                                                                                                                                          PR: 11/46
                                                                                                                                                                                                                                                                       SD: 18/46
  Phase II                                      Relapsed PSens serous OC after two courses of platinum-based chemotherapy                                                              Olaparib                                        Placebo                         PFS: 8.4 months
  Ledermann et al. ([@B81])                                                                                                                                                                                                                                            OS 29.7 months
  NCT00753545                                                                                                                                                                                                                                                          ORR: 12.3%
                                                                                                                                                                                                                                                                       ORR + SD: 52.9%
  Phase I                                       Refractory or recur BC (*N* = 4) and OC (*N* = 23)                                                                                     Olaparib + carboplatin                          None                            OC
  Lee et al. ([@B99])                                                                                                                                                                                                                                                  PR: 8/23
  NCT01237067                                                                                                                                                                                                                                                          SD: 11/23
  Phase I                                       Advanced solid tumors *N* = 87, including BC (26%) and OC (7%), of which 12 *BRCA*ut^mut^                                              Olaparib + carboplatin ± paclitaxel             None                            ORR: 14/87 (16%)[^b^](#tfn6){ref-type="table-fn"}
  van der Noll et al. ([@B90])                                                                                                                                                                                                                                         CR: 5%
  NCT00516724                                                                                                                                                                                                                                                          PR: 11%
                                                                                                                                                                                                                                                                       SD: 28%
  Phase II                                      Advanced PSens serous OC                                                                                                               Olaparib + carboplatin, paclitaxel              Carboplatin, paclitaxel alone   PFS: 12.2 months
  Oza et al. ([@B103])                                                                                                                                                                                                                                                 ORR: 64%
  NCT01081951                                                                                                                                                                                                                                                          
  Phase I                                       Recur or advanced EOC/TNBC                                                                                                             Olaparib + cediranib (angiogenesis inhibitor)   None                            OC
  Liu et al. ([@B82])                           *N* = 28, of which 20 OC                                                                                                                                                                                               CR: 1/18[^b^](#tfn6){ref-type="table-fn"}
  NCT01116648                                                                                                                                                                                                                                                          PR: 7/18[^b^](#tfn6){ref-type="table-fn"}
                                                                                                                                                                                                                                                                       SD: 3/18[^b^](#tfn6){ref-type="table-fn"}
  Phase I                                       Advanced solid tumors                                                                                                                  Olaparib + cisplatin                            None                            CR: 1/54[^b^](#tfn6){ref-type="table-fn"}
  Balmana et al. ([@B100])                      *N* = 54, of which 10 OC                                                                                                                                                                                               PR: 17/54[^b^](#tfn6){ref-type="table-fn"}
  NCT00782574                                                                                                                                                                                                                                                          SD: 23/54[^b^](#tfn6){ref-type="table-fn"}
  Phase I                                       Advanced solid tumors (*N* = 23, of which 6 OC)                                                                                        Rucaparib + carboplatin                         None                            OC
  Molife et al. ([@B104])                                                                                                                                                                                                                                              PR: 1/6
  NCT01009190                                                                                                                                                                                                                                                          SD: 2/6
  Phase I                                       Advanced *BRCA*ut^mut^ solid tumors, or *BRCA*t^wt^ tumors (*N* = 25, of which 4 OC)                                                   Veliparib                                       None                            *BRCA*t^wt^
  Huggins-Puhalla et al. ([@B91])                                                                                                                                                                                                                                      SD: 7/25[^b^](#tfn6){ref-type="table-fn"}
  NCT00892736                                                                                                                                                                                                                                                          
  Phase I                                       Refractory solid tumors/lymphoma                                                                                                       Veliparib                                       Cyclophosphamide                PR: 7/35[^b^](#tfn6){ref-type="table-fn"}
  Kummar et al. ([@B101])                       *N* = 35, including BC and OC                                                                                                                                                                                          SD: 6/35[^b^](#tfn6){ref-type="table-fn"}
  NCT00810966                                                                                                                                                                                                                                                          
  Phase II Kummar et al. ([@B97]) NCT01306032   Refractory progressive *BRCA*ut^mut^ OC or HGS OC                                                                                      Veliparib (V) + cyclophosphamide (C)            Cyclophosphamide (C)            V + C: PR: 3/36[^b^](#tfn6){ref-type="table-fn"}
                                                                                                                                                                                       *N* = 36                                        *N* = 38                        C: PR: 5/38[^b^](#tfn6){ref-type="table-fn"}
  Phase I                                       Met or unresect solid tumors                                                                                                           Veliparib + carboplatin and gemcitabine         None                            CR: 2/59[^b^](#tfn6){ref-type="table-fn"}
  Bell-McGuinn et al. ([@B98])                  *N* = 59, of which 39 OC, 24 of 39 *BRCA*ut^mut^                                                                                                                                                                       PR: 11/59[^b^](#tfn6){ref-type="table-fn"}
  NCT01063816                                                                                                                                                                                                                                                          Of 13 responses, 8 *BRCA*ut^mut^ OC, 3 other OC, 2 others

*^a^Data include only patients with measurable disease*.

*^b^Collective data reported*.

*recur, recurrent; *BRCA*^mut^, mutated *BRCA*; OC, ovarian cancer; BC, breast cancer; *BRCA*^wt^, *BRCA*-wild type; HGS, high-grade serous; TNBC, triple negative breast cancer; CR, complete response; PR, partial response; SD, stable disease; PSens, platinum-sensitive; PFS, progression free survival; OS, overall survival; ORR, objective response rate; EOC, epithelial ovarian cancer; BLBC, basal-like breast cancer; met, metastatic; unresect, unresectable*.

In a population of *BRCA*-positive recurrent ovarian cancer patients with a platinum-free interval of ≤12 months, olaparib was compared to pegylated liposomal doxorubicin (PLD) in a randomized Phase II trial (*N* = 97) ([@B66]) (Table [2](#T2){ref-type="table"}). Progression free survival (PFS) was not statistically significantly different for olaparib 200 or 400 mg twice daily (combined or individually) versus PLD (PFS 6.5 versus 8.8 versus 7.1 months, respectively). Where the PFS and ORR were consistent with prior studies for olaparib at 400 mg twice daily, the efficacy of PLD was higher than expected when compared with previous trials. Toxicity profiles were distinct between olaparib (nausea, vomiting, and fatigue) and PLD (stomatitis and palmar-plantar erythrodysesthesia), and overall, the drugs were well tolerated. Although olaparib did not show an improvement in PFS over chemotherapy, these results show that targeted therapy with a PARP inhibitor is as effective as chemotherapy, with potential for improved tolerability.

Other PARP inhibitors have also been studied in clinical trials including niraparib (MK4827) in both *BRCA*-positive and sporadic tumors. This compound's mechanism of action includes PARP inhibition via a novel PARP trapping mechanism ([@B67]). A Phase I study utilizing niraparib monotherapy was recently published that established a maximum tolerated dose of 300 mg/day (*N* = 100) ([@B68]) (Table [1](#T1){ref-type="table"}). Dose-limiting toxicities (DLTs) were reported in the first cycle including grade 4 thrombocytopenia at a dose of 400 mg/day. Non-hematologic DLTs included grade 3 fatigue and grade 3 pneumonitis at lower doses (30 and 60 mg/day, respectively). Common treatment-related effects were anemia, nausea, fatigue, thrombocytopenia, anorexia, neutropenia, constipation, and vomiting, but were predominantly grade 1 or 2. There were anti-tumor responses seen in the *BRCA*-mutated breast and ovarian cancer population, and these were recorded at doses \>60 mg/day. Results from this study show promise for this newer PARP inhibitor and currently there are multiple Phase III trials recruiting in *BRCA*-positive breast and ovarian, and sporadic ovarian cancer populations (NCT01905592, NCT01847274) (Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}).

###### 

**Ongoing or future PARP inhibitor trials in *BRCA 1/2*-mutated (*BRCA*^mut^) breast and ovarian cancers**.

  Trial                              Study population                                                                                  PARP inhibitor                                              Comparison therapy                                                          ClinicalTrials.gov status
  ---------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------- --------------------------------------------------
  Phase III                          Met or unresect *BRCA*ut^mut^ BC                                                                  BMN 673                                                     Physician's choice -- capecitabine, eribulin, gemcitabine, or vinorelbine   NCT01945775 Recruiting
  Phase III                          HER-2 negative met or advanced *BRCA*ut^mut^ BC                                                   Niraparib                                                   Physician's choice (select from four active comparators)                    NCT01905592 (BRAVO) Not yet open for recruitment
  Phase III                          PSens *BRCA*ut^mut^ or HGS OC w/prior CR and second CR/PR                                         Niraparib (maintenance)                                     Placebo                                                                     NCT01847274 Recruiting
  Phase III                          PSens *BRCA*ut^mut^ (stage III or IV) OC in first CR/PR                                           Olaparib (maintenance)                                      Placebo                                                                     NCT01844986 Not yet open for recruitment
  Phase III                          Relapsed PSens *BRCA*ut^mut^ OC w/prior CR and second CR/PR                                       Olaparib (maintenance)                                      Placebo                                                                     NCT01874353 Not yet open for recruitment
  Phase II                           Met or locally advanced *BRCA*ut^mut^ BC/OC                                                       Rucaparib                                                   None                                                                        NCT00664781
                                                                                                                                                                                                                                                                               Active, not recruiting
  Phase II Miller et al. ([@B105])   *BRCA*ut^mut^ BC or *BRCA*t^wt^ TNBC w/residual disease in adjuvant setting (after NAC/surgery)   Rucaparib + cisplatin                                       Cisplatin                                                                   NCT01074970 Ongoing, not recruiting
  Phase I                            Met or unresect *BRCA*ut^mut^ BC and OC                                                           Veliparib                                                   None                                                                        NCT01853306
                                                                                                                                                                                                                                                                               Recruiting
  Phase I/II                         Relapsed PRes or partially PSens *BRCA*ut^mut^ EOC                                                Veliparib                                                   None                                                                        NCT01472783
                                                                                                                                                                                                                                                                               Veli-BRCA
                                                                                                                                                                                                                                                                               Recruiting
  Phase II                           Met or advanced *BRCA*ut^mut^ BC                                                                  Veliparib                                                   Placebo and carboplatin, paclitaxel                                         NCT01506609
  Isakoff et al. ([@B106])                                                                                                             Three arms, plus temozolomide, or carboplatin, paclitaxel                                                                               Recruiting
  Phase II                           Advanced or recur *BRCA*ut^mut^ EOC                                                               Veliparib                                                   None                                                                        NCT01540565
  Coleman et al. ([@B107])                                                                                                                                                                                                                                                     Ongoing, not recruiting
  Phase I                            *BRCA*ut^mut^ solid tumors (e.g., BC and OC)                                                      Veliparib + oxaliplatin and capecitabine                    None                                                                        NCT01233505
                                                                                                                                                                                                                                                                               Recruiting
  Phase I                            Met or unresect *BRCA*ut^mut^ BC and OC                                                           Veliparib + temozolomide                                    None                                                                        NCT00526617
                                                                                                                                                                                                                                                                               Completed

*met, metastatic; unresect, unresectable; BC, breast cancer, PSen, platinum-sensitive; HGS, high-grade serous; OC, ovarian cancer; CR, complete response; PR, partial response; *BRCA*^wt^, *BRCA*-wild type; TNBC, triple negative breast cancer; NAC, neoadjuvant chemotherapy; PRes, platinum-resistant; EOC, epithelial ovarian cancer; recur, recurrent*.

###### 

**Ongoing or future PARP inhibitor trials in sporadic breast and ovarian cancers**.

  Trial                              Study population                                                                                  PARP inhibitor                                                                                  Comparison therapy                                                   ClinicalTrials.gov status
  ---------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------
  Phase III                          PSens *BRCA*ut^mut^ or HGS OC w/prior CR and second CR/PR                                         Niraparib (maintenance)                                                                         Placebo                                                              NCT01847274
                                                                                                                                                                                                                                                                                                            Recruiting
  Phase I                            Recur TNBC/HGS OC                                                                                 Olaparib + BKM120 (PI3 kinase inhibitor)                                                        None                                                                 NCT01623349
                                                                                                                                                                                                                                                                                                            Recruiting
  Phase I                            Met or unresect TNBC/serous EOC                                                                   Olaparib + carboplatin                                                                          None                                                                 NCT01445418
                                                                                                                                                                                                                                                                                                            Recruiting
  Phase I/Ib                         Relapsed stage III or IV OC                                                                       Olaparib + carboplatin and paclitaxel                                                           None                                                                 NCT01650376
                                                                                                                                                                                                                                                                                                            Recruiting
  Phase II                           Relapsed recur PSens high-grade EOC                                                               Rucaparib                                                                                       None                                                                 NCT01891344 (ARIEL2)
                                                                                                                                                                                                                                                                                                            Recruiting
  Phase II Miller et al. ([@B105])   *BRCA*ut^mut^ BC or *BRCA*t^wt^ TNBC w/residual disease in adjuvant setting (after NAC/surgery)   Rucaparib + cisplatin                                                                           Cisplatin                                                            NCT01074970 Ongoing, not recruiting
  Phase I                            Recur or residual EOC/met TNBC                                                                    Veliparib                                                                                       Pegylated liposomal doxorubicin                                      NCT01145430
  Pothuri et al. ([@B108])                                                                                                                                                                                                                                                                                  Recruiting
  Phase I                            Recur met or locally advanced unresect solid tumors (e.g., BC/OCs) with organ dysfunction         Veliparib                                                                                       Carboplatin and paclitaxel                                           NCT01366144 Recruiting
  Phase I                            Recur OC                                                                                          Veliparib                                                                                       None                                                                 NCT01459380
                                     Two arms + doxorubicin, carboplatin, and bevacizumab                                                                                                                                                                                                                   Recruiting
  Phase I                            Node-positive BC with incomplete response to NAC                                                  Veliparib                                                                                       Radiation therapy                                                    NCT01618357
                                                                                                                                                                                                                                                                                                            Recruiting
  Phase I                            Recur stage IV EOC                                                                                Veliparib + intraperitoneal floxuridine (FUDR)                                                  None                                                                 NCT01749397
                                                                                                                                                                                                                                                                                                            Recruiting
  Phase I                            Newly diagnosed stage II--IV optimally or suboptimally debulked OC                                Veliparib + paclitaxel, carboplatin, bevacizumab                                                None                                                                 NCT00989651 Recruiting
                                                                                                                                       Two parallel arms                                                                                                                                                    
  Phase II                           Stage IIA, IIIA--C TNBC                                                                           Veliparib + paclitaxel + carboplatin, followed by doxorubicin, cyclophosphamide (neoadjuvant)   Paclitaxel, carboplatin, followed by doxorubicin, cyclophosphamide   NCT01818063
  Avery et al. ([@B109])                                                                                                                                                                                                                                                                                    Recruiting
  Phase II                           Recur HGS OC                                                                                      Veliparib + temozolomide                                                                        Pegylated liposomal doxorubicin                                      NCT01113957
                                                                                                                                                                                                                                                                                                            Completed
  Phase I/II                         Recurrent, relapsed PRes or part PSens OC                                                         Veliparib + topotecan                                                                           None                                                                 NCT01690598
                                                                                                                                                                                                                                                                                                            Recruiting
  Phase II                           Recur advanced non-PSens OC                                                                       Veliparib + topotecan                                                                           None                                                                 NCT01012817
                                                                                                                                                                                                                                                                                                            Recruiting

*PSen, platinum-sensitive; *BRCA*^mut^, *BRCA 1/2*-mutated; HGS, high-grade serous; OC, ovarian cancer; CR, complete response; PR, partial response; recur, recurrent; TNBC, triple negative breast cancer; met, metastatic; unresect, unresectable; EOC, epithelial ovarian cancer; BC, breast cancer; *BRCA*^wt^, *BRCA*-wild type; NAC, neoadjuvant chemotherapy; PRes, platinum-resistant*.

Rucaparib (CO-338/AG-014699, also previously PF-01367338) was recently evaluated in Phase I and II studies in advanced solid tumors, including *BRCA*-positive breast and ovarian cancers. The PARP inhibitor as monotherapy and in combinations with cytotoxic chemotherapy is under investigation. In a standard dose-escalation fashion, a Phase I/II study (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) is currently evaluating rucaparib monotherapy in advanced solid tumors (*N* = 29) including ovarian/primary peritoneal (*N* = 7) and breast (*N* = 17) cancer patients ([@B69]). Thus far, no DLTs at 360 mg twice daily (study not yet complete) have been reported. To date, two PRs were seen in one *BRCA*-positive ovarian cancer, and one *BRCA*-positive breast cancer patient at 300 mg daily dosing during the sixth week of therapy. Ten additional patients (ovarian *N* = 5, breast *N* = 4, and colorectal *N* = 1) have experienced stable disease (SD) at \>12 weeks so far; seven of which are *BRCA*-positive. Overall the disease control rate (PR + SD \> 12 weeks) for ovarian cancer patients is 86% (6/7). Further results are anticipated from this study. These promising results to date have supported ARIEL2, a Phase II study of rucaparib in platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer patients, which is currently recruiting patients (Table [6](#T6){ref-type="table"}).

BMN 673, a novel, highly potent PARP 1/2 inhibitor, demonstrated high efficacy in preclinical studies ([@B70]). BMN 673 elicits DNA repair biomarkers at much lower concentrations \[PARP1 half maximal inhibitory concentration (IC~50~) \<1 nmol/L\] than earlier generation PARP inhibitors, i.e., olaparib, veliparib, and rucaparib. Its anti-tumor activity has been tested *in vitro* and in xenograft cancer models, as monotherapy and in combination. Anti-tumor activity was seen in *BRCA1*, *BRCA2*, and *PTEN* deficient cells with a 20 to more than 200-fold greater potency than existing PARP 1/2 inhibitors. Synergism was also seen when BMN 673 was combined with temozolomide, SN38, or platinum drugs. Thus far, BMN 673 has been the most specific PARP inhibitor in its class.

The first in-human Phase I, clinical trial using BMN 673 in solid tumor patients was recently presented at ASCO 2013 ([@B71]) (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Patients with advanced solid tumors defective in DNA repair, including *BRCA*-mutated breast (*N* = 6), and ovarian (*N* = 17) cancer patients, were eligible for the stage II expansion phase at the maximum tolerated dose of 1000 mcg daily. In total, 39 patients with advanced solid tumors were enrolled, including those tumors with deleterious *BRCA* mutations. Thrombocytopenia was dose-limiting and occurred in three patients at doses 900 or 1100 mcg daily. Most potential treatment-related adverse events (AEs) were grade 1/2 and included fatigue, nausea, flatulence, anemia, neutropenia, thrombocytopenia, and alopecia. Objective responses were seen in 11/17 *BRCA*-mutated ovarian/primary peritoneal cancer patients and 2/6 *BRCA*-mutated breast cancer patients. Based on these encouraging results, the recommended dose, 1000 mcg daily, will be studied in a Phase III trial in *BRCA*-carrier metastatic or locally advanced breast cancer patients (NCT01945775) (Table [5](#T5){ref-type="table"}).

In addition to the single agent studies described above, PARP inhibitors have been combined with chemotherapy in *BRCA* mutation-related malignancies. Lee et al. in a Phase I/Ib study, utilized olaparib, in combination with carboplatin, in a standard dose-escalation study design in *BRCA 1/2*-mutated breast and ovarian cancers (*N* = 45) ([@B72]) (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). The recommended Phase II dose was 400 mg twice daily for 14 days with carboplatin AUC 5. As noted in several other trials utilizing olaparib, and other PARP inhibitors, myelosuppression was frequently present with grade 3/4 AEs (neutropenia 42%), as well as, thrombocytopenia (20%), anemia (13%), carboplatin-hypersensitivity (9%), and fatigue (7%). Responses included one CR in a breast cancer patient that was durable (duration of 17 months), and a PR in 15/34 (44%) ovarian cancer (duration 3--28+ months) and 6/8 breast cancer (duration 5--24+ months) patients. Prolonged SD was seen in 14/34 (41%) ovarian cancer patients for as long as 25 months and for 11 months in a breast cancer patient. Remarkably, the overall clinical benefit rate was 100% in breast cancer patients and 85% in ovarian cancer patients. A summary of Phase I--III studies utilizing PARP inhibitors in *BRCA* 1/2-mutated breast and ovarian cancers can be found in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

Sporadic breast and ovarian cancer trials {#S7-2}
-----------------------------------------

The earliest trials reported for sporadic TNBCs evaluated iniparib (BSI-201) in combination with gemcitabine and carboplatin. The Phase II trials showed promising anti-tumor activity, prolonged median progression-free survival, and median overall survival (OS) with minimal overall toxicity ([@B73]). Disappointingly, the results were not significant in the Phase III trial ([@B74]). There are a number of potential explanations for the lack of efficacy seen in the Phase III study, including the heterogeneity within the subtypes of TNBC. Importantly, it was discovered that iniparib was actually not a PARP inhibitor, at physiologic concentrations. Rather, iniparib was shown to cause telomere-centric DNA damage ([@B75]).

There are also a number of reported and ongoing studies with "true" PARP inhibitors in sporadic TNBCs, although, only a few studies that have been published in final format. A Phase I/II study of mention explored the use of olaparib in combination with paclitaxel in the first or second-line setting for metastatic TNBC patients (*N* = 19) ([@B76]) (Table [3](#T3){ref-type="table"}). Notably, patients were treated with olaparib 200 mg daily with paclitaxel 90 mg/m^2^ weekly for 3 of 4 weeks and 15 of the patients had had previous taxane-based therapy. Thirty-seven percent of patients had a PR, although, there were significant dose modifications due to the greater than expected rate of neutropenia, even despite use of growth factor support. While taxanes are proven agents in TNBC ([@B77]--[@B79]), this class is not typically thought to be a potentiating agent for PARP inhibitors. Most studies have used a platinum agent for potentiation, exploiting the DNA damage/dysfunctional DNA repair pathways concept. Perhaps utilizing two agents that are active in different parts of the cell cycle would potentially target more tumor cells, overall, including those in different phases of growth. Additionally, the utility of PARP inhibitor/taxane-based combination may have potentially overcome taxane resistance. There are ongoing studies with platinum and taxane combinations with a PARP inhibitor. Early looks at efficacy are promising ([@B80]).

Similarly in ovarian cancer, there have been a number of studies evaluating PARP inhibitors with chemotherapy, including in the maintenance setting. Ledermann et al. studied olaparib in the maintenance setting after second CR in platinum-sensitive recurrent serous ovarian cancer patients. This was a Phase II, randomized, double-blinded, placebo-controlled trial (*N* = 265) ([@B81]) (Table [4](#T4){ref-type="table"}). Median PFS was statistically significant between the groups, 8.4 versus 4.8 months, in the olaparib and placebo arms, respectively (*p* \< 0.001). OS was not significantly different (29.7 versus 29.9 months in the olaparib and placebo groups, respectively). Further studies are needed to identify a population of patients that may experience greater clinical benefit, such as those with *BRCA 1/2*-mutations or those with a BRCAness phenotype.

Combination therapies with PARP inhibitors have also been investigated in sporadic ovarian and breast cancers, specifically with other novel targeted agents. Cediranib, an anti-angiogenesis agent, was studied with olaparib in recurrent epithelial ovarian or TNBCs (*N* = 28, 20 ovarian and 8 breast) ([@B82]) (Tables [1](#T1){ref-type="table"}--[4](#T4){ref-type="table"}). Patients were enrolled to four dose levels and the recommended Phase II dose was cediranib 30 mg daily and olaparib 200 mg twice daily was based on one occurrence of grade 4 neutropenia (≥4 days) and one of grade 4 thrombocytopenia with dosages of cediranib 30 mg daily and olaparib 400 mg twice daily. Seventy-five percent of patients experienced grade 3 or higher toxicities with grade 3 hypertension and fatigue, occurring in 25 and 18% of subjects, respectively. Despite the frequent hematologic and non-hematologic toxicities, the ORR was 44% in the evaluable ovarian cancer population (*N* = 18). Sixty-one percent of ovarian patients had clinical benefit (including those with SD). None of the breast cancer patients experienced clinical response, but two patients had SD for \>24 weeks. A summary of Phase I--III studies utilizing PARP inhibitors in sporadic breast and ovarian cancers can be found in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

Platinum and PARP Inhibitor Resistance {#S8}
======================================

*BRCA 1/2*-deficient cancers are known to be hypersensitive to platinum agents which are thought account for, in part, better overall prognosis for those patients with *BRCA 1/2*-germline mutation-related breast and ovarian cancer. Not all patients respond to platinum, however, and indeed, it is likely that the majority of tumors will eventually become platinum-resistant. Additionally, not all patients with *BRCA 1/2*-germline mutations or those with an expected BRCAness phenotype respond to PARP inhibition. Several mechanisms of resistance to both agents have been hypothesized and are likely to be multifactorial in etiology. Current evidence suggests that secondary mutations occur in the *BRCA1* or *BRCA2* gene restoring the wild type *BRCA 1/2* open reading frame which may provide return of DNA repair through a functional HR pathway. These reversion mutations are thought to lead to platinum resistance, as well as PARP inhibitor resistance ([@B83]--[@B87]). It is imperative that these secondary mutations are identified to help modulate therapeutic management of these populations. Of interest, PARP inhibitor resistance may, in fact, not affect subsequent therapy response, including subsequent platinum regimens ([@B88]).

Conclusion {#S9}
==========

Poly (ADP-ribose) polymerase inhibitors have shown promising activity as both monotherapy and in combination with cytotoxic chemotherapy in BRCA 1/2-mutated cancers. More recently, this concept has been implicated in sporadic high-grade serous ovarian cancers and TNBCs. Like platinum agents, PARP inhibitors have been efficacious in this population. Published data from the TCGA network further support this therapeutic strategy by showcasing the genomic similarities between high-grade serous ovarian cancers and TNBCs. It may be worthwhile in the future to study new drug therapies in tandem in these two populations. New strategies are needed to combat tumor resistance mechanisms, such as secondary mutations that revert *BRCA* genes to wild type, to both platinum agents and PARP inhibitors. Future directions for PARP inhibition include when best to use these agents, in what combinations, and precisely, how to define the optimal populations that will get the most benefit.
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